InSCREENeX GmbH is a spin-off of the Helmholtz Centre for Infection Research.

The founder is Dr. rer. nat. Roland Schucht. InSCREENeX GmbH is located in state-of-the-art laboratory and office facilities within the Helmholtz Centre for Infection Research, Braunschweig, Germany.

Using state of the art genetic manipulation techniques to engineer cells, InSCREENeX offers novel, user friendly, mam- malian cell systems as decision tools for drug development processes. These developed systems have the benefits of biological relevance and convenience.

The discovery of novel drugs is a challenging, costly, time con- suming and inefficient process. To address these problems, InSCREENeX offers innovative and unique SCREENflex™ and CI-SCREEN™ product solutions to expedite drug discovery and enable biologically relevant tests in vitro to provide complementary, cellular screening tools aimed at all stages of the drug development process.


  • Roland Schucht (Ph.D.)
    Roland Schucht
    Managing Director
  • Tobias May (Ph.D.)
    Tobias May
    Managing Director

Our Current Projects

European Regional Development Fund (EFRE)

Quality control of 3D cell culture constructs via Scanning Laser Optical Tomography SLOT

Together with the Laser Centre Hannover we develop a technology for the high troughput quality control of physiological 3D cell culture constructs. The Laser Centre Hannover provides the optical know-how (Scanning Laser Optical Tomography), while we establish physiological relevant 3D cell culture constructs based on our cell lines.

EU-EFRE-LogoThis project has received funding from the European Union’s Regional Development Fund, project no 85031498.

HORIZON 2020: SME Instrument Phase-1

O-POINTED: Osteoarthritis patient cohorts in the dish - personalised cellular drug development tools for osteoarthritis precision medicine

We have been selected for Horizon 2020 SME Instrument Phase-1 funding. We will evaluate the feasibility of generating personalised and expandable cell lines from a cohort of more than 50 osteoarthritis patients. O-POINTED represent osteoarthritis patient variability including all the main disease phenotypes (bone-, cartilage-, synovium-driven). Learn more in our detailed press release.

EU-LogoThis project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 868644.

BMWi - ZIM - Zentrales Innovationsprogramm Mittelstand

Skalierbare humane 3D Gewebemodelle aus funktional immortalisierten Glattmuskulaturzellen für die Wirkstoffentwicklung

A Germany-Canada partnership to develop game-changing bioprinted models of tissue contraction. InSCREENeX will generate functional smooth muscle cells for the research partners.

A Collaboration with Aspect Biosystems and Fraunhofer ITEM.

HORIZON 2020 INFRAIA-2016-1: VetBioNet

Veterinary Biocontained facility Network for excellence in animal infectious disease research and experimentation

The principal aim of the VetBioNet infrastructure project is to establish and maintain a comprehensive network of pre-eminent high-containment (BSL3) research facilities, academic institutes, international organisations and industry partners that is dedicated to advance research on epizootic and zoonotic diseases and to promote technological developments. InSCREENeX generates multiple animal cell lines for our project partners.

EU-VetBioNet-Logo This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 731014.

Our Completed Projects

BMBF: Alternativmethoden zum Tierversuch

BBB on Chip - Ein mikrofluidisches In-vitro-Modell der Blut-Hirn-Schranke für das Wirkstoff- und Arzneimittelscreening

The aim of this project is the establishment of a novel, innovative in vitro model of blood-brain barrier (BBB). A multidisciplinary team will carry out this project using a human, cell culture-based, microfluidic approach to develop an organotypic BBB on chip system. Once installed this in vitro test system will be used for pharmacokinetic testing of new active pharmaceutical ingredients and drug formulations, primarily in the preclinical phase of drug development.

A Collaboration with the TU Braunschweig IMT and IPT.

BMBF: KMU innovativ

Etablierung von humanen Darmgewebemodellen für das präklinische Hochdurchsatzscreening

The aim of the project is the establishment of standardized intestinal in vitro test systems, which closely resembles the physiology of the human intestine. These test systems will enable a highly predictable screening process that determines the absorption of drug candidates or chemical substances.

A Collaboration with the Fraunhofer IGB and the Fraunhofer TLZ-RT.

Stay in touch